跳至主要内容
临床试验/NCT06177535
NCT06177535进行中(未招募)不适用

The Effect of Oral Kavalactones on Cortisol, Measures of Burnout, and Motivation in Nurses

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2024年8月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Mayo Clinic
入组人数
200
试验地点
2
主要终点
Changes in Cortisol

研究概览

简要总结

This research study is being done to assess the impact of taking Kava extract (Piper methysticum), a dietary supplement on cortisol in a healthy nursing population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Surgical services nurses at Mayo Clinic in Rochester, MN.
  • •Able to participate fully in all aspects of the study.
  • •Willing to use birth control for the duration of the study (if of childbearing potential).
  • •Understood and signed study informed consent.

排除标准

  • •Pregnant, nursing, or trying to conceive.
  • •Persons with a menstrual cycle who are not willing and able to use an approved contraceptive during the study (female sterilization (tubal ligation, hysterectomy), IUD or another implant, oral or injectable contraceptive, contraceptive patch/ring, diaphragm/cervical cap, male sterilization (vasectomy), male condom, female condom, sponge/spermicide) (Persons who do not have sex with men can participate without the use of an approved contraceptive).
  • •Use of kava or kava-containing products within the past 8 weeks.
  • •Any prior adverse reaction or known sensitivity or allergy to kava or related botanicals (peppers).
  • •Use of acetaminophen that cannot be discontinued or replaced with an NSAID during the study.
  • •Use of oral corticosteroids (e.g., hydrocortisone) or other steroids (e.g., prednisone).
  • •Alcohol use greater than 1 drink per day.
  • •Use of kratom within the past 8 weeks.
  • •Recent history of clinical depression or anxiety diagnosis.
  • •Known significant liver disease or dysfunction.
  • •Known significant kidney disease or dysfunction.
  • •Known Addison's or Cushing's Disease.
  • •Known catecholamine imbalance or medication use which influences catecholamine levels.
  • •History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis).
  • •Recent history or acute disease or unstable medical condition.
  • •Surgery planned during the course of the trial.
  • •A known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

研究组 & 干预措施

Placebo Group

Placebo Comparator

Subjects will receive placebo for 28 days

干预措施: Placebo (Drug)

Kava Group

Experimental

Subjects will receive Kavalactones for 28 days

干预措施: Kavalactones (Dietary Supplement)

结局指标

主要结局

Changes in Cortisol

时间窗: Baseline, 4 weeks

Blood serum cortisol levels reported in micrograms per deciliter (mcg/dL)

次要结局

  • Change in burnout(Baseline, 4 weeks)
  • Change in sleep(Baseline, 4 weeks)
  • Change in quality of life(Baseline, 4 weeks)
  • Change in cognition(Baseline, 4 weeks)
  • Change in motivation(Baseline, 4 weeks)
  • Adverse events(4 weeks)
  • Change in mood(Baseline, 4 weeks)
  • Change in stress(Baseline, 4 weeks)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Brent A. Bauer

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验